Fortress Biotech, Inc.
FBIO
NASDAQ·Healthcare·Biotechnology·Mkt cap $93.0M
$2.80
▼ -0.36%
P/E
—
Mkt Cap
$93.0M
52-Wk Range
$2.18–$4.53
52-Week Range
$2.18 - $4.53
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified product portfolio spanning multiple therapeutic areas reducing dependency on single assets
- Established commercial infrastructure with FDA-approved dermatology products generating current revenue
- Strategic partnerships with leading research institutions and pharmaceutical companies accelerating development
- Proprietary platforms including oligonucleotide and gene therapy technologies enabling competitive differentiation
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Advancement of late-stage clinical candidates toward regulatory approval and commercialization
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+1.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying FBIO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 16, 2026
AUG 13, 2026
Reported EPS of -$0.08 vs -$0.20 consensus (+60.0% surprise). Revenue of $18.7M vs $18.3M expected (+2.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+60.0%
Revenue trend · last 8Q
—
—
+1%
+10%
+21%
+6%
+22%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.6M
$15.1M
$13.1M
$16.4M
$17.6M
$16.1M
$16.0M
$17.8M
Margins · last 8Q
Gross
0.0%
Operating
-56.1%
Profit
-13.9%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How FBIO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related